SCHEMBL21788282

SCHEMBL21788282

CC(C)NC(=O)C(CCCNC(N)=O)NC(=O)C(NC(C)C)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FURIN P09958 7/20 0.38
▸ SIRT5 Q9NXA8 1/20 0.36
▸ NMT2 O60551 1/20 0.34
▸ NMT1 P30419 1/20 0.34
▸ C3AR1 Q16581 1/20 0.34
▸ NPY4R P50391 5/20 0.33
▸ NPY1R P25929 3/20 0.33
▸ NPY2R P49146 3/20 0.33
▸ NPY5R Q15761 3/20 0.33
▸ SIRT6 Q8N6T7 1/20 0.33
▸ SIRT1 Q96EB6 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23126444 1.00 FURIN (0.38) FURINSIRT5NMT2NMT1C3AR1
SCHEMBL22067692 1.00 FURIN (0.38) FURINSIRT5NMT2NMT1C3AR1
SCHEMBL21788261 0.91 FURIN (0.36) FURINSIRT5NMT2NMT1C3AR1
SCHEMBL23900963 0.91 FURIN (0.36) FURINSIRT5NMT2NMT1C3AR1
SCHEMBL23079360 0.90 FURIN (0.39) FURINSIRT5NMT2NMT1C3AR1
SCHEMBL27378298 0.90 FURIN (0.37) FURINSIRT5NMT2NMT1NPY4R
SCHEMBL24349699 0.89 SIRT5 (0.36) FURINSIRT5C3AR1NPY4RNPY1R
SCHEMBL20803561 0.89 C3AR1 (0.34) FURINSIRT5C3AR1SIRT6SIRT1
SCHEMBL21788077 0.89 FURIN (0.38) FURINSIRT5NMT2NMT1C3AR1
SCHEMBL24173258 0.89 C3AR1 (0.34) FURINSIRT5C3AR1SIRT6SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073436-A2 COMPOSITIONS AND USES THEREOF SOLVE THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
US-11779663-B2 Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-10-10 — — US disclosed
US-20230165931-A1 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-06-01 — — US disclosed
US-20230165930-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-06-01 — — US disclosed
US-20230149502-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-18 — — US disclosed
US-20230115871-A1 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD (CN) 2023-04-13 — — US disclosed
US-20230010108-A1 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-01-12 — — US disclosed
US-20230001001-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-01-05 — — US disclosed
US-20210393790-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2021-12-23 — — US disclosed
US-20210369855-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2021-12-02 — — US disclosed
US-20210169896-A1 A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES HANGZHOU DAC BIOTECH CO., LTD. (CN) 2021-06-10 — — US disclosed
US-20210052747-A1 SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF HANGZHOU DAC BIOTECH CO., LTD. (CN) 2021-02-25 — — US disclosed
US-20200069814-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052747-A1 SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF SLC25A1, GCDH, FH FURIN 1796/4885SIRT5 513/4885NMT2 52/4885
US-20230165930-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, CD2BP2, TEK FURIN 837/4885SIRT5 4732/4885NMT2 165/4885
US-20200069814-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE CD4, MCL1, CCNB1 FURIN 2643/4885SIRT5 3829/4885NMT2 1338/4885
US-20230165931-A1 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, CD2BP2, CD4 FURIN 802/4885SIRT5 4695/4885NMT2 149/4885
US-20210369855-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE CD4, MCL1, CCNB1 FURIN 2643/4885SIRT5 3829/4885NMT2 1338/4885
US-20230001001-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE CD4, MCL1, CCNB1 FURIN 2643/4885SIRT5 3829/4885NMT2 1338/4885
US-20210169896-A1 A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES PBDC1, BRD2, CD79B FURIN 3602/4885SIRT5 2667/4885NMT2 1557/4885
US-20230010108-A1 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP DAO, DDO, DCLRE1A FURIN 1992/4885SIRT5 851/4885NMT2 663/4885
US-20210393790-A1 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE CD4, MCL1, CCNB1 FURIN 2643/4885SIRT5 3829/4885NMT2 1338/4885
US-20230115871-A1 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS CD2BP2, EPCAM, CD74 FURIN 1792/4885SIRT5 4312/4885NMT2 728/4885
US-11779663-B2 Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof SLC25A1, GCDH, FH FURIN 1796/4885SIRT5 513/4885NMT2 52/4885
US-20230149502-A1 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, CD2BP2, TEK FURIN 837/4885SIRT5 4732/4885NMT2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback